Bioethics News

How CRISPR Yanked Jennifer Doudna Out of the Ivory Tower

June 27, 2017

Be the first to like.
Share

Jennifer Doudna remembers a moment when she realized how important CRIPSR—the gene-editing technique that she co-discovered—was going to be. It was in 2014, and a Silicon Valley entrepreneur had contacted Sam Sternberg, a biochemist who was then working in Doudna’s lab. Sternberg met with the entrepreneur in a Berkeley cafe, and she told him, with what he later described to Doudna as “a very bright look in her eye that was also a little scary,” that she wanted to start applying CRISPR to humans. She wanted to be the mother of the first baby whose genome had been edited with the technique. And she wanted to establish a business that would offer a menu of such edits to parents.

Nothing of the kind could currently happen in the U.S., where editing the genomes of human embryos is still verboten. But the entrepreneur apparently had connections that would allow her to offer such services in other countries. “That’s a true story,” Doudna told a crowd at the Aspen Ideas Festival, which is co-hosted by the Aspen Institute and The Atlantic. “That blew my mind. It was a heads-up that people were already thinking about this—that at some point, someone might announce that they had the first CRISPR baby.”

Be the first to like.
Share

The Atlantic

Source: Bioethics Bulletin by the Berman Institute of Bioethics.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.